

Catalog Number: HZ-1030-GMP

Data Sheet





Animal Component-Free

Human cell expressed

Tag-Free


Endotoxin Free

Product Description


Animal-free Recombinant Human Oncostatin M is expressed in human 293 cells as a monomeric glycoprotein with an apparent molecular mass of 30 kDa. This higher molecular mass is due to glycosylation and is not seen in the E. coli expressed form of this cytokine (22kDa). Glycosylation contributes to stability in cell growth media and other applications. This product is produced in a human cell expression system with serum-free, chemically defined media.

| Alternative Names | oncostatin M, OSM | | | |
|--------------------|--|--|--|--|
| Accession Number | P13725 | | | |
| Source | Human Embryonic Kidney cells (HEK293). HEK293-derived OSM protein | | | |
| Species Reactivity | human | | | |
| Adventitious Virus | Adventitious Virus Master Cell Bank tested Negative for Adventitious Viruses | | | |

| Specifications | | | | | |
|-------------------|--|---|--|--|--|
| Test | Method | Specification | | | |
| Activity | Dose-dependent cytotoxicity of the human TF -1 cell line (human erythroleukemic indicator cell line) | 0.1-1.5 ng/mL | | | |
| Molecular Mass | SDS-PAGE | 32 kDa reduced, 28 kDa non-reduced, monomer, glycosylated | | | |
| Purity | SDS-PAGE | >95% | | | |
| Endotoxin | LAL | <0.1 EU/µg | | | |
| Mycoplasma | PCR | Not Detected | | | |



GMP Recombinant human OSM (HZ-1030-GMP) stimulates dose-dependent proliferation of the TF-1 human erythroleukemic indicator cell line. Cell number was quantitatively assessed by PrestoBlue® Cell Viability Reagent. TF-1 cells were treated with increasing concentrations of GMP recombinant OSM for 96 hours. The EC50 was determined using a 4-parameter non-linear



Purity of recombinant human OSM was determined by SDSpolyacrylamide gel electrophoresis. The protein was resolved in an SDS- polyacrylamide gel in reducing and non-reducing conditions and stained using Coomassie blue.

www.ptglab.com

Document #: FR-QA118-101 Rev 0 Data Sheet Version #: Proteintech Group, Inc.

5500 Pearl Street, Suite 400 Rosemont, IL 60612 t: 1-888-478-4522; f: 1-312-455-8408 Email: proteintech@ptglab.com

| Preparation | | | | |
|---|---|--|--|--|
| Shipping Temperature | | | | |
| Formulation | Formulation 1x PBS, See Certificate of Analysis for details | | | |
| Reconstitution Briefly centrifuge the vial before opening. It is recommended to reconstitute the protein to 0.2 mg/mL in sterile 1xPB containing 0.1% endotoxin-free recombinant human serum albumin (HSA). Gently swirl or tap vial to mix. | | | | |

| Stability and Storage | Product Form | Temperature Conditions | Storage Time (From Date of Receipt) |
|-----------------------|---------------------------|------------------------------------|--|
| | Lyophilized | -20°C to -80°C | Until Expiry Date |
| | Lyophilized | Room Temperature | 2 weeks |
| | Reconstituted as per CofA | -20°C to -80°C | 6 months |
| | Reconstituted as per CofA | 4°C | 1 week |
| | | Avoid repeated freeze-thaw cycles. | |

Proteintech GMP Quality Policy HumanKine® GMP Proteins

Invitro recombinant protein production can be prone to variability due to various reasons ranging from quality of raw materials to inconsistency in the process. Therefore, HumanKine®, a proteintech brand's GMP proteins are produced and tested under an ISO 13485 certified quality management system in a clean room facility. Proteintech manufactures the GMP HumanKine® products according to the applicable sections in the following documents: USP Chapter 1043 (Ancillary Materials for Cell, Gene, and Tissue-Engineered Products, USP Chapter 92 (Growth Factors and Cytokines Used in Cell Therapy Manufacturing), WHO TRS, No. 822, 1992 Annex 1 (Good Manufacturing Practices for Biological Products), Ph. Eur. General Chapter 5.2.12, and EudraLex – Volume 4 – Part IV (Guidelines on GMP specific to ATMPs). Proteintech strives to achieve the utmost quality GMP raw material ensuring all applicable guidelines are taken into consideration.

The QMS is built to provide our customers with consistent and pure product delivered by documented processes, qualified personnel, validated processes, qualified equipment, qualified vendors, and a stringent final product release process. Although the final product release process is important, Proteintech performs in-process QC steps after each major manufacturing stage. Production records and facilities may be available for an inspection by approved personnel.

Our GMP policy covers all the aspects of production; from raw materials, facility, equipment, and Instruments to training and personal hygiene of staff. It also guarantees that the process is explicit, validated and well documented for transparency and traceability.

www.ptglab.com

Document #: FR-QA118-101 Rev 0
Data Sheet Version #:

Proteintech Group, Inc.

5500 Pearl Street, Suite 400 Rosemont, IL 60612 t: 1-888-478-4522; f: 1-312-455-8408 Email: proteintech@ptglab.com